RxDoctor Payments Data

Holly Gross, MD

Ophthalmology · Frederick, MDNPI 1164498598

Payments from drug & device makers

$1,871in general payments, 2019–2025

Across 43 payments — averaging $43.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$528
  • AbbVie$277
  • NEW World Medical,inc.$223
  • Shire North American Group Inc$144
  • Bausch & Lomb Americas Inc.$122
  • Integra Lifesciences Corporation$119
  • plus $458 from 9 others

What the payments were for

  • Food & beverage$1,79996%
  • Education$362%
  • Gifts$372%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,871 in reported general payments places this provider in the 55th percentile of 493 ophthalmology providers in Maryland.

See all ophthalmology providers in Maryland

Medicare billing

Part B allowed, 2024
$541,575
Medicare patients
1,823
Services billed
3,936

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine81$121,585
XiidraLifitegrast39$55,388
LumiganBimatoprost61$42,302
Cyclosporine23$12,728
MieboPerfluorohexyloctane/Pf17$12,652
Alphagan PBrimonidine Tartrate16$10,245
RhopressaNetarsudil Mesylate13$8,846
CombiganBrimonidine Tartrate/Timolol11$6,669
Brimonidine Tartrate45$6,559
Travoprost28$6,456
Prednisolone Acetate119$4,420
Latanoprost323$4,297
Ketorolac Tromethamine100$1,843
MoxifloxacinMoxifloxacin Hcl88$1,806
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat95$1,622

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Alphagan P, Combigan$277$180,801169 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo$122$68,04056 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 493 ophthalmology providers in Maryland.

Other ophthalmology in Frederick

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →